Physician profile
Michael A Trueba
NPI 1649769837
$941.71
in general payments reported to CMS, 2019-2025
14 companies · $86.06 in 2025
The $86.06 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.00 · 2022: $24.63 · 2023: $64.02 · 2024: $740 · 2025: $86.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $890.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $350.84 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $85.60 | 2024 | |
| Lilly USA, LLC | $77.54 | 2024 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $75.47 | 2024 | |
| Astellas Pharma US INC | $68.99 | 2024-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $57.51 | 2023-2024 | Airsupra |
| Genentech USA, INC. | $51.63 | 2021-2022 | |
| Pfizer INC. | $41.98 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $34.29 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.91 | 2024 | Jardiance |
| Merck Sharp & Dohme LLC | $17.96 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Esperion Therapeutics, INC. | $15.76 | 2024 | Nexletol |
| Glaxosmithkline, LLC. | $15.13 | 2024 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.10 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Trueba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.